OBP: CEO Jacob Modumo FMD Vaccine Suspension Amid Pricing Probe

• Dr. Jacob Modumo, acting CEO of Onderstepoort Biological Products (OBP), has been suspended over allegations of serious misconduct related to FMD vaccine pricing.
• Minister of Agriculture Willie Aucamp initiated the suspension process after presenting the OBP board with evidence of alleged excessive markups on FMD vaccine sales.
• OBP, a state institution, is legally mandated not to profit from FMD vaccine sales, especially during South Africa's largest FMD outbreak.
• The allegations claim OBP purchased FMD vaccines for R45 and resold them for R70-R130, violating its public interest obligation.
• This incident highlights ongoing concerns regarding state-owned enterprise procurement ethics and OBP's troubled history of mismanagement and unaccounted funds.

As a government entity, OBP is bound by an overarching obligation to operate in the public interest, which includes avoiding exorbitant markups on vital agricultural supplies.

Dr. Jacob Modumo, the acting Chief Executive Officer of Onderstepoort Biological Products (OBP), has been suspended by the state-owned enterprise's board. This action follows an urgent meeting convened by Minister of Agriculture Willie Aucamp, who assumed his portfolio on June 30. During the meeting, Minister Aucamp presented the board with information detailing serious misconduct allegations related to the pricing of foot and mouth disease (FMD) vaccines, directly implicating the OBP CEO Jacob Modumo FMD vaccine suspension.

The board subsequently issued a notice to Dr. Modumo, informing him of their intention to suspend him and granting him a five-day period to present reasons why the suspension should not proceed. Should the provided explanations be deemed insufficient, the suspension will remain in effect pending the outcome of a comprehensive independent investigation. Minister Aucamp underscored that this measure is precautionary, and no definitive finding of guilt has been made against the acting CEO at this stage. The core of the allegations centers on the claim that OBP procured FMD vaccines from Biogénesis at a cost of R45 per dose, only to resell them at significantly higher prices, ranging from R70 to R130.

Onderstepoort Biological Products, as a state institution, bears the critical responsibility for both importing and manufacturing animal vaccines, including those for FMD. Crucially, OBP is explicitly mandated not to generate a profit from the sale of these essential FMD vaccines to farms. This directive is particularly pertinent given South Africa's current struggle with its largest FMD outbreak in history, placing immense financial strain on farmers. The Minister of Agriculture has unequivocally stated that OBP should not exploit this crisis for undue financial gain, emphasizing the government's obligation to ensure cost-effective and efficient vaccine procurement to support the agricultural sector.

This incident highlights the stringent public sector pricing regulations South Africa expects from its state-owned enterprises. As a government entity, OBP is bound by an overarching obligation to operate in the public interest, which includes avoiding exorbitant markups on vital agricultural supplies. The allegations of South Africa FMD vaccine pricing allegations against OBP directly challenge these foundational principles of state-owned enterprise procurement ethics ZA, especially when farmers are already grappling with the substantial economic burden imposed by the ongoing FMD outbreak.

The suspension of the OBP CEO Jacob Modumo FMD vaccine suspension unfolds against a backdrop of long-standing challenges within the FMD vaccine supply chain and governance issues at OBP. South Africa currently relies heavily on imports for the vast majority of its FMD vaccines, primarily from Biogénesis Bagó in Argentina and Dollvet in Turkey. The country's cattle population, estimated at 12 to 14 million, requires approximately 25 million vaccine doses annually for optimal protection, a volume that these international suppliers are capable of meeting.

Onderstepoort Biological Products misconduct is not a new concern; the entity has a troubled history. It ceased manufacturing FMD vaccines around 2005 due to mismanagement, losing its production capabilities. Despite receiving a R500 million grant in 2013 to rebuild its capacity, an audit later revealed that a significant portion of these funds remained unaccounted for, and OBP still does not manufacture FMD vaccines. This history of financial irregularities and operational failures underscores the importance of the current Willie Aucamp OBP investigation. Furthermore, the controversy follows a recent legal battle where farmer organizations successfully obtained an interim ruling from the Gauteng High Court in Pretoria in May, allowing them to purchase vaccines directly. This acrimonious case was a significant factor in the previous agriculture minister, John Steenhuisen, losing his position. An agreement with Minister Aucamp now permits farmers to acquire vaccines via veterinarians, provided they submit usage details to the Department of Agriculture.

This development signals heightened scrutiny on the governance and procurement practices of South African state-owned enterprises (SOEs), particularly regarding pricing transparency and ethical conduct in critical sectors. Lawyers and compliance officers should advise clients on reviewing their engagement with SOEs to ensure compliance with fair pricing and public interest mandates, mitigating exposure to similar misconduct investigations or regulatory challenges.

Source: Original reporting via GroundUp